Published

01 Apr 26

Updated

24 Jul 26

Views

186

Not Invested

ImmunityBioIBRX

Fair Value

US$15

Share price24 Jul

US$7.5749.5% undervalued

1Y196.86%

7D-0.92%

Expanded Immunotherapy Platform And Automation Will Transform Long Term Earnings Power

AnalystHighTarget

Analyst High Target compiles bullish analysts opinions to create narratives which represent one standard deviation above the consensus price target, using forecasted revenue and earnings figures, as well as the transcripts of earnings calls

Published

01 Apr 26

Updated

24 Jul 26

Views

186

Not Invested

Shared on 24 Jul 26

Fair value Decreased 35%

IBRX: FDA Review Timeline For Bladder Cancer Will Drive Future Upside

ImmunityBio faces lawsuits tied to an FDA warning about how it marketed Anktiva, just as the FDA starts the clock on a key review for its bladder cancer use. The next big swing comes from whether the agency signs off on the expanded use and how the company’s new BCG supply deal changes the outlook.

97 views

Fair Value vs Share Price

US$15

vs US$7.5749.5% undervalued

130.6%

Revenue growth

42.5%

Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on ImmunityBio

Fair value estimate changes
Narrative and analyst updates
Key company announcements

Company analysis

High growth potential and fair value.

Market capUS$8.0b

PB-7.7x

Estimated Growth49.7%

Dividend YieldN/A

Full analysis

CEO & management

Richard Adcock

CEO

5.1yrs

CEO Tenure

A biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases.